proNGF Measurement in Cerebrospinal Fluid Samples of a Large Cohort of Living Patients With Alzheime...
proNGF Measurement in Cerebrospinal Fluid Samples of a Large Cohort of Living Patients With Alzheimer's Disease by a New Automated Immunoassay
About this item
Full title
Author / Creator
Publisher
Lausanne: Frontiers Research Foundation
Journal title
Language
English
Formats
Publication information
Publisher
Lausanne: Frontiers Research Foundation
Subjects
More information
Scope and Contents
Contents
The discovery of new biomarkers for Alzheimer's disease (AD) is essential for an accurate diagnosis, to conceive new strategies of treatments, and for monitoring the efficacy of potential disease-modifying therapies in clinical trials. proNGF levels in the cerebrospinal fluid (CSF) represent a promising diagnostic biomarker for AD, but its validati...
Alternative Titles
Full title
proNGF Measurement in Cerebrospinal Fluid Samples of a Large Cohort of Living Patients With Alzheimer's Disease by a New Automated Immunoassay
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_9f863c2f399044808e37accc3fedca7e
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9f863c2f399044808e37accc3fedca7e
Other Identifiers
ISSN
1663-4365
E-ISSN
1663-4365
DOI
10.3389/fnagi.2021.741414
